Disease relevance of Cupressus

• Refolding of the Cupressus arizonica major pollen allergen Cup a1.02 overexpressed in Escherichia coli [1].

High impact information on Cupressus

• An allergenic extract from Cupressus arizonica pollen was prepared with two extraction steps followed by ammonium sulfate precipitation, giving a protein yield of about 3% [2].
• Recently, the Cupressus arizonica major allergen, Cup a1, has been cloned and expressed [3].
• A monoclonal antibody (5E6), specific for a carbohydrate epitope detectable on components of Cupressus arizonica pollen extract, has been produced and characterized [4].
• Roles of jasmonate and ethylene signalling and their interaction in yeast elicitor-induced biosynthesis of a phytoalexin, beta-thujaplicin, were investigated in Cupressus lusitanica cell cultures [5].
• RESULTS: Direct RAST, RAST inhibition, and SDS-PAGE data indicated that the PPT C. arizonica pollen extract showed the most allergenic potential, and it can be considered representative of the Cupressus spp [6].

Biological context of Cupressus

• Signal transduction and metabolic flux of beta-thujaplicin and monoterpene biosynthesis in elicited Cupressus lusitanica cell cultures [7].

Associations of Cupressus with chemical compounds

• To obtain a full-length complementary DNA for Cup a 1, the major allergen of Cupressus arizonica pollen [8].
• Multiple signalling pathways mediate fungal elicitor-induced beta-thujaplicin biosynthesis in Cupressus lusitanica cell cultures [9].
• Rapid isolation, characterization, and glycan analysis of Cup a 1, the major allergen of Arizona cypress (Cupressus arizonica) pollen [10].
• Suspension cell cultures of Cupressus lusitanica produce beta-thujaplicin, a tropolone found mostly in Cupressaceae heartwood [11].
• Production of beta-thujaplicin in Cupressus lusitanica suspension cultures fed with organic acids and monoterpenes [12].

Gene context of Cupressus

• CASE REPORT: a 66-year-old woman presented with symptoms of allergic rhinitis and asthma due to sensitization to Cupressus arizonica [13].
• CONCLUSION: This study has shown that: The KCNO modified Cupressus arizonica extract has a reduced IgE binding capacity; This monomeric allergoid is safe and effective administrated by the oromucosal route in clinical respiratory allergy to Cupressaceae and devoid of any side effect [14].

Analytical, diagnostic and therapeutic context of Cupressus

• Molecular cloning of major allergen from Cupressus arizonica pollen: Cup a 1 [8].
• Quantification of the major allergen from cypress (Cupressus arizonica) pollen, Cup a 1, by monoclonal antibody-based ELISA [15].
• METHODS: Mixed or single Cupressus arizonica, lusitanica and sempervirens pollen extracts precipitated with ammonium sulfate (PPT) were compared by direct RAST, RAST inhibition and SDS-PAGE techniques [6].
• The diagnosis was assessed on a clinical hivernal symptomatology of allergic rhinitis, and/or asthma, positive skin test and RAST, and nasal provocation test to Cupressus arizonica [14].

References